Enterprise Value
1.148B
Cash
528.1M
Avg Qtr Burn
-43.67M
Short % of Float
23.33%
Insider Ownership
6.52%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nirogacestat (gamma secretase inhibitor) Details Desmoid tumors Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Mirdametinib Details NF1-associated Plexiform Neurofibromas | Phase 2b Update | |
Nirogacestat Details Cancer, Ovarian cancer, recurrent ovarian granulosa cell tumors | Phase 2 Data readout | |
Mirdametinib (MEK inhibitor) Details Cancer, Glioma | Phase 1/2 Data readout | |
Mirdametinib+lifirafenib Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
Nirogacestat (gamma secretase inhibitor) Details Multiple myeloma, Cancer | Phase 1/2 Data readout | |
Mirdametinib + fulvestrant (Faslodex) Details Breast cancer, Cancer | Phase 1/2 Update | |
Nirogacestat (gamma secretase inhibitor) Details Cancer, Multiple myeloma | Phase 1b Data readout | |
BGB-3245 (RAF Fusion and Dimer Inhibitor) Details Solid tumor/s, Cancer | Phase 1 Update |